Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349666 | 0.91 | PPARG (0.49) | KMT2AMEN1PPARGPPARAHTT | |
| SCHEMBL350032 | 0.86 | PPARG (0.46) | KMT2AMEN1PPARGPPARAALDH1A1 | |
| SCHEMBL347672 | 0.85 | CYP3A4 (0.53) | KMT2AMEN1HTTALDH1A1LMNA | |
| SCHEMBL350012 | 0.84 | HTT (0.44) | KMT2AMEN1HTTALDH1A1LMNA | |
| SCHEMBL348004 | 0.83 | TTR (0.53) | KMT2AMEN1HTTALDH1A1LMNA | |
| SCHEMBL13521899 | 0.82 | HTT (0.47) | KMT2AMEN1HTTALDH1A1LMNA | |
| SCHEMBL347720 | 0.82 | HTT (0.47) | KMT2AMEN1HTTALDH1A1LMNA | |
| SCHEMBL349501 | 0.82 | ALDH1A1 (0.52) | KMT2AMEN1PPARGPPARAHTT | |
| SCHEMBL347221 | 0.82 | LCK (0.54) | KMT2AMEN1HTTALDH1A1LMNA | |
| SCHEMBL349154 | 0.82 | ALDH1A1 (0.42) | KMT2AMEN1HTTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247602-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120016029-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-01-19 | — | — | US | disclosed |
| US-8071807-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110144160-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2307362-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100004331-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2010003120-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010003127-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016029-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | KMT2A 4646/4885MEN1 4751/4885PPARG 35/4885 |
| US-20100004331-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | KMT2A 4646/4885MEN1 4751/4885PPARG 35/4885 |
| US-20110144160-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | KMT2A 4646/4885MEN1 4751/4885PPARG 35/4885 |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | KMT2A 4618/4885MEN1 4760/4885PPARG 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.